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Background: This study aimed to evaluate the relationship between the expression levels of selected integrin
genes and proteins and cell differentiation, TNM stage, histological type and other variables potentially associated
with the progression and dissemination of colorectal carcinoma (CRC).
Methods: A total of 114 patients (63 men and 51 women) were treated for CRC between 2006 and 2009, including 25
(21.9%) TNM I, 39 (34.2%) TNM II, 34 (29.8%) TNM III, and 16 (14.1%) TNM IV. Regarding grade, 91 (79.8%) were grade II,
14 (12.2%) were grade III and nine (7.8%) were grade I. Reverse-transcription polymerase chain reaction (RT-PCR) and
tissue microarray (TMA) methods were used to examine the expression levels of the genes ITGAV, ITGA3, ITGA5, ITGB5,
and ITGA6, and their proteins, respectively.
Results: In relation to TNM staging, ITGB5 and ITGA3 were over-expressed in stages III versus I. These results were
confirmed by TMA analysis. In terms of age, ITGA5 was under-expressed according to RT-PCR, but over-expressed by TMA
in patients over 60 years, while ITGA5 gene and protein levels were increased in mucinous carcinomas. In addition ITGAV
gene and protein levels were elevated in tumors with neural invasion, and ITGA6 gene and protein were over-expressed
in cases with venous invasion. All these results were significant at P < 0.05.
Conclusion: The results of this study suggest that over-expression of some integrins is associated with TNM III stage,
increased risk of vascular and neural invasion, and mucinous histology in patients with CRC.
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The increasing availability of molecular biology tools has
revealed the coexistence of numerous processes during
carcinogenesis, from imbalances in the cell cycle to the
development of a neoplastic tissue with invasive charac-
teristics. Extracellular matrix (ECM) proteins interact
directly with cell surface receptors/adhesion molecules
to initiate signal transduction pathways and modulate
different processes [1] that participate in various cellular
events such as adhesion, migration, proliferation, cell
differentiation, apoptosis and angiogenesis [2]. Integrins* Correspondence: mfdenadai@uol.com.br
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reproduction in any medium, provided the orappear to act as adhesion receptors for ECM proteins
such as collagen, laminin and fibronectin, and also play
a role in cell–cell adhesion [3].
Integrins display a heterodimeric structure composed of
an α subunit, with a large extracellular domain containing
various regions with cationic links and a short intracellular
domain, and a β subunit, which has a large extracellular
domain with repeated sequences of amino acids, containing
a large number of cysteine residues. To date, 18 α subunits
and eight β subunits have been identified [4,5]. The major-
ity of integrin binding occurs at its extracellular domain,
with the peptide sequence Arg-Gly-Asp, which is present
in many ECM proteins [6,7], acting as a transmembrane
connector between the extracellular ligand and the cyto-
plasmic environment, thus participating in bidirectional
signaling by different cell types [8].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical characteristics of patients
Parameter Number (%)
Age (yr) <60 56
>60 58
Sex Male 63 (55.3%)
Female 51 (44.7%)
Tumor location Colon 82 (71.9%)
Rectum 32 (28.1%)
Differentiation Well 9 (7.8%)
Moderate 91 (79.8%)
Poor 14 (12.2%)
Histologic type Adenocarcinoma 97 (85.1%)
Mucinous carcinoma 17 (14.9%)
Histological characteristics Inflammatory infiltrate 93 (81.6%)
Perineural invasion 8 (7.1%)
Vascular invasion 21 (18.4%)
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ena that are implicated in processes such as cell growth
and development, apoptosis, adhesion, migration, inva-
sion, phagocytosis and cell morphology [9-11]. Studies
by Von Lampe et al. [12] showed that the expression
levels of α3 and α5 integrins were very low in adenomas,
and absent in the majority of colorectal carcinomas
(CRCs). In contrast, the α6 integrin maintains its expres-
sion in adenomas, but its expression levels are very low
in malignancies with infiltrative growth characteristics,
suggesting an association with CRC progression [12].
Some studies [13] have reported a crucial role for the
αV integrin in the migration of cells in the colon, but
the dynamics of this integrin and its effects are still
poorly understood. Some integrins show different ex-
pression profiles during tumor growth and progression,
suggesting their potential as targets for the diagnosis
and therapy of cancer [14-16].
Methods
Clinical characteristics
This study included patients of either gender aged ≥18 years
who underwent surgery at the Colorectal Surgery Depart-
ment, Barretos Cancer Hospital, Brazil, between 2006 and
2009, and who had cryopreserved tumor samples obtained
during surgery and paraffin-embedded tissue available for
further histopathological analysis. Patients who had re-
ceived neoadjuvant treatment (chemotherapy or radiother-
apy), patients in whom the primary CRC site had not been
removed, and patients with a previous or current diagnosis
of other primary malignancies in any location of the body,
other than non-melanoma skin cancer or cervical carcin-
oma in situ, were excluded from the study. A total of 114
patients with colon cancer (63 men, 51 women) were there-
fore included. Their median age was 54.5 years (range,
24–85 years). This study was approved by the Barretos
Cancer Hospital Ethics Committee, São Paulo, Brazil.
Project number: 128/2008.
The histological characteristics commonly associated
with tumor dissemination and progression were catego-
rized as follows: venous invasion (presence vs. absence),
lymphatic vessel invasion (presence vs. absence), perineural
invasion (presence vs. absence), lymph node metastasis
(presence vs. absence), distant metastases (presence vs.
absence), and TNM grouping ( I vs. II, I vs. III, I vs. IV , I:
control group) (AJCC 2002, 6th edition).
To test the hypothesis that integrins might be associated
with CRC progression and dissemination, we examined
differences in their gene and protein expression levels with
respect to the histological covariates mentioned above,
using both reverse-transcription polymerase chain reaction
(RT-PCR) and the immunohistochemical (IHC) tests using
the tissue microarray technique (TMA). The use of human
tissue for research was approved by the InstitutionalReview Board, and the design of this study followed the
principles of the Helsinki Declaration and complied with
the principles of good clinical practice. The clinical charac-
teristics of the patients are presented in Table 1.Tumor specimens
Cryopreserved samples were embedded in medium for
frozen tissue specimens (Tissue-Tek OCT; Sakura
Finetek, Torrance, Calif., USA) and fitted into a cryostat
(CM1850 UV; Leica Microsystems, Nussloch, Germany)
for histological analysis. Slides mounted with sections of
4 μm thickness were subjected to the hematoxylin-eosin
staining technique (Merck, Darmstadt, Germany) and
then analyzed by a pathologist to ensure that the se-
lected samples represented the general histology of the
tumor and were free of necrosis or calcifications. Areas
of interest were identified microscopically and marked
for macrodissection. These slides were used as ‘guides’
to select and cut tissues in the cryostat. For each sample,
sterile individual scalpel blades were used. After
discarding inappropriate areas for RNA extraction, the
tissue was mechanically macerated with liquid nitrogen
and transferred to 1.5-ml microtubes, which were RNase
and DNase free and contained 1,000 μl TRIzol (Invitrogen,
Carlsbad, Calif., USA). RNA was extracted according to the
manufacturer’s instructions, and RNA quantification was
performed using a spectrophotometer (Thermo Scientific
NanoDrop 2000). The quality and integrity of the RNA
were verified by the presence of 28S and 18S bands in
Figure 1 Expression of integrins protein in CRC by IHC staining. ( X 400). A , C, E, G, I, Low expression of α3, α5 , α6, αv, β5 integrins
protein, respectively. B, D, F, H , J, Overexpression of α3, α5, α6, αv, β5 integrins protein respectively.
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assure the absence of degradation of the RNA samples.
RNA was purified with the RNeasy mini kit (Qiagen,
Valencia, Calif., USA) following the manufacturer’srecommendations, eluted with 30 ml of water free of
RNase and DNase (Qiagen), quantified spectrophoto-
metrically at a wavelength of 260 nm (NanoVue; GE
Healthcare, Chicago, Ill., USA) and stored at −80°C until
Table 2 Analysis of the expression of genes according to the categorization of covariates with descriptions of the fold
regulation and statistical differences (Mann–Whitney U test; p values are shown in parentheses) in the study cohort
(n = 114)
Covariates Comparison performed Genes
Control vs. test group ITGA3 ITGA5 ITGA6 ITGB5 ITGAV
FR ( p ) FR ( p ) FR ( p ) FR ( p ) FR ( p )
Gender Female vs. male - 1.81 (0.377) 1.20 (0.467) 1.22 (0.599) 1.04 (0.360) 1.17 (0.068)
Age <60 vs. ≥60 years 1.27 (0.301) −1.54 (0.016) 1.15 (0.524) 1.14 (0.267) −1.22 (0.128)
Histological classification Adeno. vs. mucinous 4.02 (0.700) 1.25 (0.029) −1.05 (0.358) 1.34 (0.815) −1.02 (0.983)
Tumor grading Low vs. high grade 2.94 (0.752) 1.88 (0.05) −1.34 (0.098) 1.36 (0.889) 1.08 (0.371)
Venous invasion Absent vs. present 1.78 (0.653) −1.13 (0.510) 1.42 (0.047) 1.12 (0.718) 1.02 (0.818)
Lymphatic vessel invasion Absent vs. present 1.18 (0.619) −1.47 (0.119) 1.10 (0.878) −1.03 (0.643) −1.03 (0.914)
Perineural invasion Absent vs. present −4.11 (0.782) 1.00 (0.971) 1.36 (0.544) −1.74 (0.686) 1.37 (0.028)
Clinical stage (TNM) I vs. III 2.40 (0.025) 1.08 (0.642) - 1.47 (0.869) 1.30 (0.042) 1.14 (0.348)
FR, Fold regulation; Adeno., Adenocarcinoma. Significant values are bold.
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first-strand synthesis SuperMix (Invitrogen), as recom-
mended by the manufacturer. The reaction was carried
out in a 20 μl final volume containing 2 μg of total RNA
with oligo(dT)20 as a primer. The transcription phase was
carried out in a thermal cycler (Mastercycler® ep Gradient
S; Eppendorf, Hamburg, Germany), and the cDNA was
stored at −20°C for future reactions.
Analysis of genes of interest
After RNA extraction and cDNA synthesis, tumor samples
from the 114 cases of CRC were analyzed by RT-PCR for
the amplification of 84 ECM genes using the Extracellular
Matrix and Adhesion Molecules PCR Array plate (PAHS-
013; SABiosciences, Qiagen, Valencia, CA, USA). Of these
84 genes, ITGAV, ITGA3, ITGA5, ITGB5, ITGA6 were se-
lected. Each sample was analyzed using an ECM and
adhesion molecule PCR array (PAHS-013; SABiosciences,
Qiagen) plate. A mixture was prepared containing 1.275 ml
of buffer with SYBR Green (2× Master Mix SABiosciences
RT2 qPCR), 1.173 ml RNAse-free H2O and 102 μl of the
cDNA sample. Next, 25-μl aliquots were added to each
well of the 96-well plate. Reactions were performed in a
thermal cycler (ABI 7500; Applied Biosystems, Foster City,Table 3 Description of the tissue expression of integrins
according to categorization of IHC expression by TMA
technique (n = 114)
Integrin Low expression High expression
n % n %
α3 55 48.2 59 51.8
α 6 61 53.5 53 46.5
α 5 53 46.5 61 53.5
α V 62 54.4 52 45.6
β 5 63 55.3 51 44,7CA, USA), according to the following protocol: 95°C for
10 min, and 40 cycles at 95°C for 15 s and 60°C for 1 min.
Data analysis was performed using the ΔΔCt method from
the website http://pcrdataanalysis.sabiosciences.com/pcr/
arrayanalysis.php. Expression of each gene was classified
as ‘high’ or ‘low’, based on the level of expression after
grouping patients by the covariates of interest.
Immunohistochemical assays
The immunohistochemical expression of proteins related
to the selected genes was evaluated by TMA. The expres-
sion levels of the markers p53, Bcl-2, Ki67, epidermal
growth factor receptor (EGFR) and vascular endothelial
growth factor (VEGF) were also evaluated. Histological
sections (4 μm thick) were stained with hematoxylin-eosin
and reviewed, and the sites for TMA sampling were also
selected. TMA blocks were prepared using Beecher appar-
atus (Beecher Instruments, Silver Spring, MD, USA),
according to the manufacturer’s instructions. The TMA
block sections were attached to the slides using an adhe-
sive tape system (Instrumedics Inc., Hackensack, NJ,
USA). The samples were cut to a thickness of 4 μm, and a
small roller was used to press the section onto the tape.
The tape with the attached histological section was then
placed on a resin-coated slide (part of the adhesive system
kit) and pressed with the same roller for better adherence.
The slides were then placed under UV light for 20 min
and were exposed to a solvent solution (TPC) for a further
20 min. The slides were dried, and the tape was removed.
The sections were paraffin-embedded and stored in ideal
cooling conditions.
Sections of TMA blocks were mounted onto glass
slides coated with silane (3-aminopropyltriethoxysilane)
and dried for 30 min at 37°C, deparaffinized with xylene
and rehydrated through a series of graded alcohols. En-
dogenous peroxidase activity was blocked by incubating
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gen peroxide for 20 min, followed by washing in distilled
water. The sections were initially submitted to heat-
induced epitope retrieval using citrate buffer (pH 9.0) in an
uncovered pressure cooker (Eterna®, Nigro, Araraquara,
Brazil). The slides were immersed in the buffer solution,
and the pressure cooker was closed with the safety valve
open; once the saturated steam was released, the safety
valve was lowered until full pressurization was achieved.
Endogenous peroxidase was blocked with 3% hydrogen
peroxide (10 vol. hydrogen peroxide) for three washes of
10 min each. The slides were washed again in running dis-
tilled water, followed by 10 mM phosphate-buffered saline,
pH 7.4, for 5 minutes. Primary antibodies were then
applied, and the slides were incubated overnight at 8°C.
The following primary monoclonal antibodies were pur-
chased from Abcam (Cambridge, MA, USA) and used at a
1:400 dilution: mouse anti-α6 integrin (100 μg), rabbit
anti-β5 integrin (500 μl), mouse anti-α3 integrin (100 μg),
mouse anti-αV integrin (100 μg), and mouse anti-α5 integ-
rin (100 μl). The following non-ECM primary antibodies
were also used: anti-p53 (1:300), anti-Bcl-2 (1:600), anti-
VEGF (1:100), anti-Ki67 (1:500), and anti-EGFR (1:100).Specimen classification based on immunohistochemical
results
Preliminary tests were performed to identify the optimal
antibody concentrations and to select positive and nega-
tive controls using the dilution data supplied by the
manufacturer.Table 4 Analysis of IHC expression of Integrins expression ac
Covariates Categorization
αV α3
- / + p - / +
Age < 60 years 27/29 0.259 27/29
≥ 60 years 35/23 28/30
Gender Male 34/29 1.000 28/35
Female 28/23 27/24
Histological type Adeno 54/43 0.601 48/49
Mucinous 8/9 7/10
Tumor grading Low grade 56/44 0.401 50/50
High grade 6/8 5/9
Venous invasion Absent 58/35 <0.001 52/41
Present 4/17 3/18
Perineural invasion Absent 62/44 0.001 52/54
Present 0/8 3/5
Clinical stage I-II 59/5 <0.001 53/11 <
III- IV 3/47 2/48
−/+ = Low/high expression; Adeno.,Adenocarcinoma. Significant values are bold.After washing the primary antibody with phosphate-
buffered saline, the slides were incubated with biotin-free
polymer in the Advance ™ visualization system (DAKO) for
30 min. A freshly prepared solution containing 1 drop of
DAB (3.3 - diaminobenzidine tetrahydrochloride; Sigma,
St. Louis, Mo., USA) with 1 ml of substrate (DAKO) was
applied for 5 min on each slide.
Tissue expression of markers was categorized dichotom-
ously as either ‘over-expression’ or ‘under-expression’,
according to the ‘quick score’ method [17,18], which multi-
plies the percentage of stained cells (P) by the intensity of
staining (I). The percentages of stained tumor cells were
Scored as follows: 0 (absence of stained cells), 1 (<25%
stained cells), 2 (26–50% stained cells) and 3 (>50% stained
cells). Scores for the intensity of cell staining were as
follows: 1 (mild intensity), 2 (moderate intensity) and 3
(intense staining). A gene product was thus considered to
be over-expressed when the final score was >4 (P × I = >4),
while markers with a final score ≤4 were considered to be
under-expressed.
Stroma and tumor cells were not treated separately
during immunohistochemical analysis, and only the
expression levels of markers on tumor cells were consid-
ered for scoring (Figure 1).
Statistical analysis
Data from real-time PCR were analyzed using the
RT2 Profiler PCR Array Data Analysis program, ver-
sion 3.4 (SABioscience, Qiagen) (http://pcrdataanalysis.
sabiosciences.com/pcr/arrayanalysis.php). Statistical as-
sociations between integrin gene and protein expressioncording to covariates in patients with CRC (n = 114)
Integrins
α5 α6 β5
p - / + p - / + p - / + p
1.00 49/7 <0.001 30/26 1.000 30/26 0.851
4/54 31/27 33/25
0.451 29/34 1.000 36/27 0.452 35/28 1.00
24/27 25/26 28/23
0.502 51/ 46 0.003 61/36 0.002 53/44 0.684
2/15 0/17 10/7
0.397 48/52 0.569 57/43 0.083 57/43 0.394
5/9 4/10 6/8
0.001 42/51 0.631 61/32 <0.001 54/39 0.239
11/10 0/21 09/12
0.781 49/57 1.000 59/47 0.142 60/46 0.464
4/4 2/6 3/5
0.001 28/36 0.572 40/24 0.038 49/15 <0.001
25/25 21/29 14/36
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using non-parametric Mann–Whitney U tests for quan-
titative variables and χ2 tests for qualitative variables.
When the χ2 assumptions were not met, Fisher’s exact
test was used.
The associations between integrin genes and the non-
ECM markers EGFR, VEGF, p53, Bcl-2 and Ki67 (ordinal
variables) were measured using the Spearman correlation
coefficient. The Spearman coefficient may range from −1
to +1, and the closer the calculated value is to these
extremes (−1 or +1), the greater the association between
the variables [19].
The level of significance was set at 5% (P < 0.05), and
the data were analyzed using SPSS software (Statistical
Package for Social Sciences; SPSS, Chicago, IL, USA),
version 15.0. The Shapiro-Wilk test was used to verify
that the data were normally distributed.Results
Integrin gene expression in colon cancer tissues analyzed
by RT-PCR
The ITGA3 gene was significantly over-expressed in TNM
III tumors compared with TNM I tumors (2.40 -fold regu-
lation; P = 0.025). ITGA5 was over-expressed in histo-
logical mucinous type compared with adenocarcinomas
(1.25-fold regulation; P = 0.029), and under-expressed in
patients aged over 60 years, compared with those under
60 (1.54-fold regulation; P = 0.016). The ITGB5 gene was
over-expressed in TNM III compared with TNM I stages
(1.30-fold regulation; P = 0.042). The ITGA6 gene was
over-expressed in tumors with venous invasion compared
with those without (1.42-fold regulation; P = 0.047), while
the ITGAV gene was over-expressed in tumors with
perineural invasion, compared with those without (1.37-Table 5 Expression levels of integrins genes in relation to
clinicopathological variables and immunohistochemical
scores (p < 0.05)





α6 Over - vascular
invasion +
Over - vascular invasion + Yes
Over - mucinous No
Over - TNM III,IV No
αV Over - neural invasion + Over - neural invasion + Yes
Over - TNM III,IV No
Over - vascular invasion + No
α5 Over – mucinous Over - mucinous Yes
Under - age >60 Over – age >60 No
β5 Over - TNM III Over - TNM III,IV Yes
α3 Over - TNM III Over - TNM III,IV Yes
Over- vascular invasion + Nofold regulation; P = 0.02). Regarding the degree of cell
differentiation, there were no significant differences in
expression levels of gene (grades I-II compared with grade
III) . A summary of these results is shown in Table 2.
Immunohistochemical study of integrins in colon cancer
tissues
Table 3 shows the frequencies of high and low expres-
sion of the gene products of interest for the 114 patients
included in this study.
Regarding the degree of cell differentiation, there were
no significant differences in expression levels of any pro-
teins between tumors scored as immunohistochemical
grades I-II compared with grade III (P > 0.05). In terms of
TNM staging, however, ITGB5, ITGAV, ITGA3 and
ITGA6 proteins were significantly over-expressed in stages
III and IV compared with stages I and II (P <0.05).
In relation to the presence of peritumoral inflammatory
infiltrate, there were no significant differences in expression
levels of any of the evaluated proteins (P > 0.05) in relation
to the presence or absence of inflammatory infiltrate. Re-
garding the presence vs. the absence of venous invasion,
however, ITGAV, ITGA3 and ITGA6 were significantly
over-expressed in the presence of venous invasion
(P < 0.05). In addition, ITGAV was significantly over-
expressed in tumors showing perineural invasion (P < 0.05),
and ITGA5 and ITGA6 were significantly over-expressed
in mucinous-type tumors compared with adenocarcinoma
(P < 0.05).
There were no significant differences in expression levels
between genders for any of the analyzed proteins (P > 0.05).
However, ITGA5 protein was over-expressed in patients
under 60 years old compared with those over 60 years
(P < 0.05). Table 4 shows the results of immunoexpression
of these markers according to the clinicopathological covar-
iates studied.
For each integrin gene that was under- or over-
expressed according to array tracking, the corresponding
protein was analyzed by antigen-antibody reaction on
TMA slides. Protein expression levels validated the RT-
PCR results, with the exception of ITGA5 expression in
relation to age. A summary of these results is presented
in Table 5.Relationship between integrin expression and epithelial
markers
The associations between integrin genes and the epithelial
markers EGFR, VEGF, p53, Bcl-2 and Ki67 were analyzed
using the Spearman correlation coefficient. Significant
associations were found between ITGAV/EGFR (r = 0.774;
P < 0.001), ITGA3/EGFR (r = 0.744; P < 0.001) and p53/
Ki67 (r = 0.875; P < 0.001).
The Spearman correlation is presented in Table 6.
Table 6 Spearman coefficient correlation (r, two-tailed model) for associations between IHC expression of integrins
proteins and other markers (n = 114)
ITGB5 ITGA5 ITGAV ITGA6 ITGA3 EGFR VEGF KI67 P53 BCL2
ITGB5 ρ 1,000 0,025 0,380 0,116 0,480 0,428 −0,049 0,104 0,057 −0,018
Valor de p . 0,791 0,000* 0,218 0,000* 0,000* 0,603 0,270 0,548 0,852
ITGA5 ρ 0,025 1,000 −0,100 0,199 −0,020 −0,003 0,086 −0,205 −0,193 0,018
Valor de p 0,791 . 0,291 0,034* 0,832 0,976 0,366 0,028* 0,040* 0,853
ITGAV ρ 0,380 −0,100 1,000 0,135 0,708 0,774 −0,103 0,262 0,215 −0,106
Valor de p 0,000* 0,291 . 0,152 0,000* 0,000* 0,277 0,005* 0,022* 0,263
ITGA6 ρ 0,116 0,199 0,135 1,000 0,231 0,219 0,055 0,134 0,086 −0,088
Valor de p 0,218 0,034* 0,152 . 0,013* 0,019* 0,559 0,154 0,366 0,352
ITGA3 ρ 0,480 −0,020 0,708 0,231 1,000 0,744 0,051 0,155 0,100 0,018
Valor de p 0,000* 0,832 0,000* 0,013* . 0,000* 0,587 0,101 0,288 0,853
EGFR ρ 0,428 −0,003 0,774 0,219 0,744 1,000 −0,082 0,375 0,335 −0,054
Valor de p 0,000* 0,976 0,000* 0,019* 0,000* . 0,384 0,000* 0,000* 0,569
VEGF ρ −0,049 0,086 −0,103 0,055 0,051 −0,082 1,000 −0,165 −0,150 0,334
Valor de p 0,603 0,366 0,277 0,559 0,587 0,384 . 0,080 0,111 0,000*
KI67 ρ 0,104 −0,205 0,262 0,134 0,155 0,375 −0,165 1,000 0,875 −0,124
Valor de p 0,270 0,028 0,005* 0,154 0,101 0,000* 0,080 . 0,000* 0,189
P53 ρ 0,057 −0,193 0,215 0,086 0,100 0,335 −0,150 0,875 1,000 −0,107
Valor de p 0,548 0,040* 0,022* 0,366 0,288 0,000* 0,111 0,000* . 0,256
BCL2 ρ −0,018 0,018 −0,106 −0,088 0,018 −0,054 0,334 −0,124 −0,107 1,000
Valor de p 0,852 0,853 0,263 0,352 0,853 0,569 0,000* 0,189 0,256 .
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There is considerable evidence to implicate genetic alter-
ations in the rapid progression of several types of malig-
nant tumors from the early to more advanced stages.
Abnormal signaling of molecules may activate genes and
thus trigger dissemination and metastasis. The identifi-
cation of these altered molecules and their correlations
with clinical and pathological stages may help to eluci-
date the mechanisms involved in this processes.
Koivisto et al. [20] suggested that the ECM has a decisive
influence on tumor behavior, especially in processes of pro-
liferation, progression and tumor cell invasion. These inter-
actions are mediated by integrins, which play an important
role in the development of tumor invasion and metastasis.
This study highlighted the roles of the integrin membrane
receptors, which are the most-studied and well-understood
cell adhesion molecules [4,8,21]. The extracellular portion
of the integrin is known to bind to ECM proteins, while
the intracellular portion connects to cytoskeletal elements
such as actin filaments. This connection reinforces the
integrity of tissues and cell adhesion, and stabilizes cellular
protrusions during migration. This connection also repre-
sents a signaling pathway that can transmit information to
key processes such as transcriptional control, cell death,
proliferation and migration [22]. Furthermore, integrins
have been shown to be differentially expressed duringtumor growth and progression, making them potential
targets for the diagnosis and therapy of cancer [14-16,23].
In this study, we detected over-expression of the genes
for α3 and β5 integrins in more advanced tumors, in
stages III compared with stage I, which represent non-
metastatic tumors. This observation was confirmed by
TMA protein analysis, suggesting a relationship between
these integrins and tumor progression and dissemination.
According to Jinka et al. [24], over-expression of integrins
α3, α5 and α6 was directly related to the progression of
various types of malignant tumors. Haier et al. [25] studied
the expression of α2, α3, α5 and α6 integrins by immuno-
histochemistry in cell lineages from metastatic colorectal
liver carcinoma, and showed over-expression of α2 and α3
integrin in relation to dissemination potential. Another
immunohistochemical study by Toquet et al. showed
higher expression of α5 integrin in poorly differentiated
cells in grade-III tumors, compared with grades I and II
[26]. This study demonstrated a significant relationship
between α5 integrin expression and mucinous histological
type vs. adenocarcinoma, the latter of which has a better
prognosis.
A recent cell-culture study of human breast cancer and
normal epithelial tissue showed an involvement of β5
integrin in tumor progression and invasion in terms of
altered adhesion, cell architecture, and differentiation, and
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breast carcinoma cell invasion [27]. α6 Integrin regulates
multiple cellular functions, including the development of
cell invasion, migration and tumor progression [28]. How-
ever, to the best of our knowledge, the current study is the
first to demonstrate a correlation between α6 integrin gene
over-expression and venous invasion, thus connecting
tumor spread with hyper-expression of this integrin. Fur-
ther studies are needed to confirm these findings. A recent
study [29] examined breast cancer cell lineages in rats by
RT-PCR and flow cytometry, and concluded that α6 integ-
rin worked as a promoter for cell metastasis and acceler-
ated cell proliferation, indicating its involvement in tumor
progression.
Neural invasion was associated with a significantly lower
survival rate and an increased recurrence rate in patients
with rectal cancer stage III and IV [30]. In the present
study, expression of the ITGAV gene was significantly
related to the presence of perineural invasion (P = 0.02), as
confirmed by TMA analysis. Although some integrin
subtypes have been shown to be associated with perineural
invasion in prostate cancer [31] and carcinomas of the
head and neck [32], no previous study has demonstrated a
relationship between over-expression of ITGAV and the
presence of perineural invasion in CRC.
We also examined the associations between integrin
protein expression and expression of selected epithelial
markers. EGFR showed a strong correlation with αV
integrin and a moderate correlation with α3 integrin (both
P < 0.05). Other studies have suggested that integrins may
also modulate the intracellular recycling of growth factor
receptors such as EGFR [33] and VEGFR [34]. Other
authors reported that the EGFR-integrin interaction seen
in pancreatic cancer also increased the migration of colon
cancer cells through the integrins α3β1 and α6β4, and
acted in hepatocellular carcinoma through integrins α1β1
and α2β1 [35,36].
Conclusions
Increased expression levels of ITGA6 and ITGAV are re-
lated to venous invasion and neural infiltration, respect-
ively, while over-expression of ITGB5 and ITGA3 are
associated with stage III (TNM), and over-expression of
ITGA5 correlates with the presence of mucinous-type
malignant neoplasias.
Further follow-up studies, preferably with a controlled
prospective design, are necessary to establish the roles of
integrins as potential biomarkers that could predict
disease extent or outcome, and possibly contribute to
the management of patients with CRC.
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